Total Voting Rights
Hemogenyx Pharmaceuticals plc has announced that as of November 28, 2025, its total issued share capital comprises 5,917,878 ordinary shares, with no shares held in treasury, resulting in a total of 5,917,878 voting rights. This figure will serve as the denominator for shareholders calculating their notification obligations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules regarding their interests in the company's share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your HEMO notes
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 November 2025 consists of 5,917,878 ordinary shares of 1p each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 5,917,878.
The figure of 5,917,878 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.